tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hyperlipidemias D006949 73 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypoglycemia D007003 13 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Immune System Diseases D007154 3 associated lipids
Impetigo D007169 3 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Infection D007239 6 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Intertrigo D007402 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intussusception D007443 1 associated lipids
Ischemia D007511 18 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Keloid D007627 12 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Labyrinthitis D007762 2 associated lipids
Leg Injuries D007869 2 associated lipids
Legionellosis D007876 3 associated lipids
Lentigo D007911 1 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukocytosis D007964 9 associated lipids
Leukoplakia D007971 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Lichen Planus D008010 3 associated lipids
Listeriosis D008088 12 associated lipids
Liver Abscess D008100 6 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Liver Diseases D008107 31 associated lipids
Long QT Syndrome D008133 10 associated lipids
Lung Abscess D008169 1 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lymphocele D008210 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Lymphoma D008223 18 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Malacoplakia D008287 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Mastocytosis D008415 5 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Mediastinitis D008480 2 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Meningococcal Infections D008589 3 associated lipids
Meningoencephalitis D008590 4 associated lipids
Metaplasia D008679 7 associated lipids
Mite Infestations D008924 1 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Mouth Diseases D009059 5 associated lipids
Moyamoya Disease D009072 1 associated lipids
Multiple Myeloma D009101 13 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Mutism D009155 1 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Mycoses D009181 18 associated lipids
Myelitis D009187 1 associated lipids
Myxedema D009230 2 associated lipids
Nail Diseases D009260 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nephritis D009393 19 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Grenier FC et al. A whole blood FK 506 assay for the IMx analyzer. 1991 Transplant. Proc. pmid:1721264
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
O'Neill EA et al. The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. 1991 Transplant. Proc. pmid:1721298
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Ishibashi M et al. Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. 1991 Transplant. Proc. pmid:1721330
Kawauchi M et al. Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. 1991 Transplant. Proc. pmid:1721331
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Dew MA et al. Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. 1991 Transplant. Proc. pmid:1721360
Gordon RD et al. Liver transplantation under cyclosporine: a decade of experience. 1991 Transplant. Proc. pmid:1703339
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Todo S et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. 1991 Transplant. Proc. pmid:1703340
McCauley J et al. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. 1991 Transplant. Proc. pmid:1721362
Zeevi A et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. 1991 Transplant. Proc. pmid:1703341
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Carroll PB et al. Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. 1991 Transplant. Proc. pmid:1721394
Scantlebury V et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. 1991 Transplant. Proc. pmid:1721395
Carroll PB et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. 1991 Transplant. Proc. pmid:1721396
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Langrehr JM et al. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. 1991 Transplant. Proc. pmid:1721425
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Brabletz T et al. The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. 1991 Nucleic Acids Res. pmid:1707162
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Liversidge J et al. FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. 1991 Transplant. Proc. pmid:1721455
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Roat MI et al. Treatment of Cogan's syndrome with FK 506: a case report. 1991 Transplant. Proc. pmid:1721457
Carroll PB et al. The use of FK 506 in new-onset type I diabetes in man. 1991 Transplant. Proc. pmid:1721458
McAlpine JB et al. Revised NMR assignments for rapamycin. 1991 J. Antibiot. pmid:1712766
Banerji SS et al. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. 1991 Mol. Cell. Biol. pmid:1712901
Markus PM et al. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. 1991 Surgery pmid:1713358
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690
Thomson AW The immunosuppressive macrolides FK-506 and rapamycin. 1991 Immunol. Lett. pmid:1717376
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691
Steeves M et al. In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. 1991 J. Pharm. Pharmacol. pmid:1717676
Hildebrandt A et al. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. 1991 Transplant. Proc. pmid:1703694
Romanowski P et al. [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. 1991 Postepy Biochem. pmid:1725924
Unmasking immunosuppression. 1991 Lancet pmid:1717800
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458
Jamieson NV et al. Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. 1991 Clin Transpl pmid:1726459